Clinical Trial Update: A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating reduction and discontinuation strategies for TKIs imatinib, nilotinib, dasatinib, and bosutinib in BCR-ABL positive chronic my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Chronic Myeloid Leukemia in Remission

Drugs mentioned

• Bosutinib (bosutinib)
• DASATINIB (Dasatinib)
• Imatinib (imatinib)
• Nilotinib (nilotinib)

Snippet

Sponsor: National Research Center for Hematology, Russia | Conditions: Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission | Phase 2 | Status: UNKNOWN